Equity Mates Investing Podcast cover image

Searching for the Dogs of FY23 + Ren's 5 minute valuation

Equity Mates Investing Podcast

00:00

Novo Nordisk and Johnson and Johnson in 2029

I think Novo Nordisk in 2029 is going to be in a similar position to Johnson and Johnson now. The other way I could have said it is just I think right now they're getting a pay of 45 because they're in the growth phase in 2029 They'll be less growing and the market will give them 20. So yeah, let's say if we just did hypothetically as a company moves from a growth phase to a slower, more steady phase, more established business phase, they would go from a multiple of 45 to a multiple of 20. In that case, they're going from 160 share price, doubling their profits, but less multiple and they're about the same

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app